With his wealth of knowledge and experience in a broad range of commercial financing matters, Edward "Ned" Purdon guides lender, private equity, and corporate clients alike through the challenges of a deal. Whether it’s a domestic or cross-border transaction, Ned knows how to structure, negotiate, and execute secured and unsecured financings and deliver results that exceed his clients’ goals.

Ned represents clients in syndicated loans for investment grade and non-investment grade issuers, strategic and middle-market acquisition financings, asset-based lending transactions, mezzanine financings, letters of credit, intercreditor arrangements, and multicurrency facilities. He works with clients from a variety of industries, including financial institutions and private credit, private equity, energy, agriculture, health care and life sciences, and real estate investment trusts (REITs), as well as aerospace and defense, entertainment, manufacturing, retail, and telecoms. 

Prior to joining our legal practice, Ned was an associate in the New York office of an international law firm, where he represented Wall Street financial institutions in structured finance and other corporate matters.

Education and admissions


J.D., Duke University School of Law, cum laude, 2004

B.A., Indiana University, with high distinction, 2001

Bar admissions and qualifications

District of Columbia

New York

Representative experience

A New York-based private credit fund in numerous lending facilities to various life sciences and pharmaceutical companies.

An S&P 500 health care company in connection with a US$1bn investment grade syndicated revolving credit facility.

An American public aerospace and defense company in connection with a US$3bn investment grade syndicated revolving credit facility.

A public satellite launch and manufacturing company with an extensive government contracting business in a series of syndicated bank financings.

One Rock Capital Partners in a number of acquisition financings, including One Rock's acquisitions of Airxcel and Compass Chemical.

Various other private equity firms in acquisition financings, including the acquisition of a dialysis provider and a vision care product provider.

An investment fund in a US$150m financing of its Asian real estate investment portfolio.